SV1997000104A - Peptidos y compuestos que enlazan a un receptor ref.pk3281/sv - Google Patents

Peptidos y compuestos que enlazan a un receptor ref.pk3281/sv

Info

Publication number
SV1997000104A
SV1997000104A SV1997000104A SV1997000104A SV1997000104A SV 1997000104 A SV1997000104 A SV 1997000104A SV 1997000104 A SV1997000104 A SV 1997000104A SV 1997000104 A SV1997000104 A SV 1997000104A SV 1997000104 A SV1997000104 A SV 1997000104A
Authority
SV
El Salvador
Prior art keywords
peptides
compounds
link
ref
receiver
Prior art date
Application number
SV1997000104A
Other languages
English (en)
Spanish (es)
Inventor
William J Dower
Ronald W Barrett
Steven E Cwirla
Christian M Gates
Peter J Schatz
Palamaniappan Balasubramanian
Christopher R Wagstrom
Hendren Richard Wayne
Randolph B Deprince
Surekha Podduturi
Qun Yin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25071323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV1997000104(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SV1997000104A publication Critical patent/SV1997000104A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SV1997000104A 1996-12-11 1997-12-08 Peptidos y compuestos que enlazan a un receptor ref.pk3281/sv SV1997000104A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/764,640 US5869451A (en) 1995-06-07 1996-12-11 Peptides and compounds that bind to a receptor

Publications (1)

Publication Number Publication Date
SV1997000104A true SV1997000104A (es) 1998-09-18

Family

ID=25071323

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1997000104A SV1997000104A (es) 1996-12-11 1997-12-08 Peptidos y compuestos que enlazan a un receptor ref.pk3281/sv

Country Status (24)

Country Link
US (2) US5869451A (en:Method)
EP (3) EP0948539B1 (en:Method)
JP (1) JP4128225B2 (en:Method)
KR (3) KR100668546B1 (en:Method)
CN (1) CN100379760C (en:Method)
AR (2) AR010752A1 (en:Method)
AT (1) ATE420893T1 (en:Method)
AU (1) AU725731B2 (en:Method)
BR (1) BRPI9713914B1 (en:Method)
CA (1) CA2274149C (en:Method)
CO (1) CO5080768A1 (en:Method)
DE (1) DE69739219D1 (en:Method)
ES (1) ES2321038T3 (en:Method)
HR (1) HRP970683B1 (en:Method)
MA (1) MA26454A1 (en:Method)
PA (1) PA8442601A1 (en:Method)
PE (1) PE27599A1 (en:Method)
SV (1) SV1997000104A (en:Method)
TN (1) TNSN97201A1 (en:Method)
TR (2) TR199901971T2 (en:Method)
TW (1) TW515804B (en:Method)
UY (1) UY24805A1 (en:Method)
WO (1) WO1998025965A2 (en:Method)
ZA (1) ZA9711045B (en:Method)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
PT885242E (pt) * 1995-06-07 2008-06-18 Glaxo Group Ltd Péptidos e compostos que se ligam a um receptor de trombopoietina
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
CA2308317A1 (en) 1997-10-31 1999-05-14 Smithkline Beecham Corporation Novel metal complexes
CA2308135A1 (en) * 1997-10-31 1999-05-14 John G. Gleason Novel metal complexes
CA2308316A1 (en) 1997-10-31 1999-05-14 Smithkline Beecham Corporation Novel metal complexes
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
PT2319928E (pt) * 1998-10-23 2013-06-28 Kirin Amgen Inc Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1225901A2 (en) * 1999-09-21 2002-07-31 Emory University Uses and compositions for treating platelet-related disorders using anagrelide
US20030190644A1 (en) 1999-10-13 2003-10-09 Andreas Braun Methods for generating databases and databases for identifying polymorphic genetic markers
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU784746B2 (en) 1999-11-18 2006-06-08 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
EP1278778A2 (en) * 2000-05-03 2003-01-29 Amgen Inc., Modified peptides, comprising an fc domain, as therapeutic agents
US20050158838A1 (en) * 2000-06-19 2005-07-21 Dyax Corp., A Delaware Corporation Novel enterokinase cleavage sequences
ATE544785T1 (de) * 2000-12-05 2012-02-15 Alexion Pharma Inc Rationell entworfene antikörper
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
CA2441378A1 (en) 2001-03-22 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
WO2002077267A2 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
WO2002092841A2 (en) 2001-05-14 2002-11-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
WO2003044179A2 (en) * 2001-11-20 2003-05-30 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EP1501863A4 (en) 2002-05-03 2007-01-24 Sequenom Inc KINASE ANCHOR PROTEIN, PEPTIDES AND RELATED METHODS THEREOF
AU2003230027A1 (en) 2002-05-17 2003-12-02 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
ES2254725T3 (es) * 2002-06-29 2006-06-16 Aquanova German Solubilisate Technologies (Agt) Gmbh Concentrados de isoflavonas y metodos para su preparacion.
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
WO2004016264A1 (ja) 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. トロンボポエチンレセプター活性化剤ならびにそれらの製造方法
US8227411B2 (en) * 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US7166574B2 (en) 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7981862B2 (en) 2003-08-19 2011-07-19 Biosurface Engineering Technologies, Inc. Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis
EA010759B1 (ru) 2002-09-18 2008-10-30 Орто-Макнейл Фармасьютикал, Инк. Способы увеличения продукции тромбоцитов и гематопоэтических стволовых клеток
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
EP1638587A4 (en) 2003-02-14 2007-04-18 Univ Missouri RECIPROCAL PROCEDURES AND COMPOSITIONS CONCERNING PROTEASOMAL INTERFERENCE
MXPA05012314A (es) 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.
EP2336162A1 (en) * 2003-05-12 2011-06-22 Affymax, Inc. Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
JP4266028B2 (ja) * 2003-05-12 2009-05-20 アフィーマックス・インコーポレイテッド エリスロポエチン受容体に結合する新規ペプチド
HRP20120989T1 (hr) * 2003-05-12 2013-01-31 Affymax, Inc. Peptidi koji se vežu za receptor eritropoetina
CN1863783A (zh) * 2003-08-12 2006-11-15 盐野义制药株式会社 具有血小板生成素受体激动作用的化合物
EA009286B1 (ru) * 2003-08-28 2007-12-28 Орто-Макнейл Фармасьютикал, Инк. Пептиды и соединения, которые связываются с рецептором
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
WO2005063791A2 (en) 2003-12-31 2005-07-14 F. Hoffmann-La Roche Ag Process for peptide synthesis using a reduced amount of deprotection agent
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
CA2555583A1 (en) * 2004-02-20 2005-09-09 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
JP2008505928A (ja) * 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
EA200700990A1 (ru) * 2004-11-11 2008-04-28 Афимакс, Инк. Новые пептиды, которые связывают рецептор эритропоэтина
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US8552031B2 (en) 2004-12-08 2013-10-08 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
TWI399368B (zh) 2004-12-14 2013-06-21 Nissan Chemical Ind Ltd Amide compounds and thrombopoietin receptor activators
US8258258B2 (en) 2005-03-10 2012-09-04 Biontech Ag Dimeric or multimeric microproteins
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
WO2006136450A2 (en) * 2005-06-23 2006-12-28 Aplagen Gmbh Supravalent compounds
US7968542B2 (en) 2005-07-15 2011-06-28 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
EP1904488B1 (en) 2005-07-20 2013-03-06 Nissan Chemical Industries, Ltd. Pyrazole compounds and thrombopoietin receptor activators
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1947101A4 (en) 2005-11-07 2009-09-16 Nissan Chemical Ind Ltd HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
US7879318B2 (en) * 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
WO2007087428A2 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
PL2005185T3 (pl) 2006-03-22 2011-05-31 Viral Logic Systems Tech Corp Sposoby identyfikowania celów polipeptydowych
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2027151A2 (en) * 2006-05-15 2009-02-25 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
EP2025671A4 (en) 2006-06-07 2011-04-06 Nissan Chemical Ind Ltd NITROGENIC HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
US7981425B2 (en) * 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
CA2676820A1 (en) * 2007-01-31 2008-08-07 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
JP5591691B2 (ja) * 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
WO2008157824A2 (en) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Thrombopoietin peptide conjugates
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
US8183342B2 (en) * 2007-11-06 2012-05-22 Case Western Reserve University Method of treating chemotherapy-induced thrombocytopenia
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
EP2247618B1 (en) 2008-01-25 2014-06-11 Amgen, Inc Ferroportin antibodies and methods of use
EP2620448A1 (en) 2008-05-01 2013-07-31 Amgen Inc. Anti-hepcidin antibodies and methods of use
CA2755336C (en) 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2011012306A2 (en) 2009-07-30 2011-02-03 Aplagen Gmbh Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis
JP5704073B2 (ja) 2009-10-23 2015-04-22 日産化学工業株式会社 縮環へテロ環化合物及びトロンボポエチンレセプター活性化剤
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
JP6159660B2 (ja) 2010-09-22 2017-07-05 アムジエン・インコーポレーテツド 担体としての免疫グロブリンおよびその使用
WO2014159242A1 (en) 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
MA40132B1 (fr) 2014-09-11 2019-04-30 Bristol Myers Squibb Co Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
WO2016079219A1 (en) 2014-11-19 2016-05-26 Koninklijke Philips N.V. Diagnostic method employing hnl
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
BR112018073642A2 (pt) 2016-05-19 2019-02-26 Bristol-Myers Squibb Company imunomoduladores para imagiologia tep
JP7085545B2 (ja) 2016-11-07 2022-06-16 ブリストル－マイヤーズ スクイブ カンパニー 免疫修飾因子
WO2018237153A1 (en) 2017-06-23 2018-12-27 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of pd-1
US12251424B2 (en) 2017-07-26 2025-03-18 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
KR20200058506A (ko) 2017-10-03 2020-05-27 브리스톨-마이어스 스큅 컴퍼니 면역조정제
CN113905754B (zh) 2019-01-25 2025-03-11 詹森药业有限公司 减轻起疱剂和腐蚀性气体毒性作用的方法
CA3127458A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
ES2978584T3 (es) * 2019-01-25 2024-09-16 Janssen Pharmaceutica Nv Miméticos de trombopoyetina para mitigar lesiones hepáticas y promover la hipertrofia, la regeneración y el injerto celular en el hígado junto con tratamientos con radiación y/o radiomiméticos
JP2023510737A (ja) 2020-01-06 2023-03-15 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤
CN115362166A (zh) 2020-03-30 2022-11-18 百时美施贵宝公司 免疫调节剂
CN118660955A (zh) 2021-10-01 2024-09-17 詹森药业有限公司 增加祖细胞生产的方法
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2031216A1 (de) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Tag und Datum Stellvorrichtung fur Uhren mit Kalender
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5198424A (en) * 1989-03-08 1993-03-30 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) * 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
US5571508A (en) * 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) * 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
ES2181691T5 (es) * 1992-06-11 2007-10-01 Alkermes Controlled Therapeutics, Inc. Sistema de distribucion de proteina eritropoyetina.
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
CA2170357A1 (en) 1993-08-25 1995-03-02 David Digiusto Method for producing a highly enriched population of hematopoietic stem cells
WO1995011922A1 (en) * 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
GB2285446B (en) * 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
NZ281482A (en) * 1994-02-14 2000-09-29 Univ Washington The stimulation of erythropoiesis using thrombopoietin and erythropoietin
EP0668352A1 (en) * 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
CN1148408A (zh) * 1994-02-14 1997-04-23 津莫吉尼蒂克斯公司 血细胞生成蛋白及其制造材料和方法
TW565568B (en) * 1994-03-31 2003-12-11 Amgen Inc Compositions and methods for stimulating megakaryocyte growth and differentiation
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
WO1996017062A1 (en) * 1994-11-30 1996-06-06 Zymogenetics, Inc. Low molecular weight thrombopoietin
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
DE69636714T2 (de) * 1995-04-26 2007-10-18 Kyowa Hakko Kogyo Co., Ltd. G-CSF TPO Fusionsproteine
PT885242E (pt) 1995-06-07 2008-06-18 Glaxo Group Ltd Péptidos e compostos que se ligam a um receptor de trombopoietina
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체

Also Published As

Publication number Publication date
KR100679576B1 (ko) 2007-02-07
CA2274149C (en) 2008-07-15
HRP970683A2 (en) 1998-10-31
EP0948539A2 (en) 1999-10-13
WO1998025965A2 (en) 1998-06-18
AR062931A2 (es) 2008-12-17
BRPI9713914B8 (en:Method) 2021-05-25
AU5854798A (en) 1998-07-03
AR010752A1 (es) 2000-07-12
KR20060025611A (ko) 2006-03-21
PA8442601A1 (es) 2000-05-24
MA26454A1 (fr) 2004-12-20
EP2028191A1 (en) 2009-02-25
EP2336165A1 (en) 2011-06-22
TR200401638T2 (tr) 2004-11-22
TNSN97201A1 (fr) 2005-03-15
JP2001505898A (ja) 2001-05-08
BRPI9713914B1 (pt) 2017-06-20
WO1998025965A3 (en) 1998-08-13
BR9713914A (pt) 2000-02-29
ES2321038T3 (es) 2009-06-01
CO5080768A1 (es) 2001-09-25
CA2274149A1 (en) 1998-06-18
ATE420893T1 (de) 2009-01-15
TR199901971T2 (xx) 1999-12-21
DE69739219D1 (de) 2009-03-05
US6121238A (en) 2000-09-19
KR20050042505A (ko) 2005-05-09
KR20000069408A (ko) 2000-11-25
KR100625708B1 (ko) 2006-09-20
ZA9711045B (en) 1999-06-09
PE27599A1 (es) 1999-03-29
US5869451A (en) 1999-02-09
JP4128225B2 (ja) 2008-07-30
AU725731B2 (en) 2000-10-19
EP0948539B1 (en) 2009-01-14
HRP970683B1 (en) 2002-10-31
UY24805A1 (es) 2000-12-29
TW515804B (en) 2003-01-01
KR100668546B1 (ko) 2007-01-16
CN100379760C (zh) 2008-04-09
CN1245504A (zh) 2000-02-23

Similar Documents

Publication Publication Date Title
SV1997000104A (es) Peptidos y compuestos que enlazan a un receptor ref.pk3281/sv
MX9709315A (es) Peptidos y compuestos que se unen a un receptor de trombopoyetina.
WO1999003822A8 (en) Bicyclic metabotropic glutamate receptor ligands
MY113497A (en) Peptides and compounds that bind to a receptor
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
PL333301A1 (en) Pyrimidine halogens
AU3508497A (en) Androgen receptor modulator compounds and methods
EP0897726A4 (en) ANTI-CURRENT AGENT
JO2034B1 (en) Isotopes of the hormone peptide its uses and the chemical compounds it contains
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
AU7657387A (en) Apoprotein b-100 specific monoclonal antibodies
EA199800753A1 (ru) Бензотиофены, составы их содержащие и способы с их использованием
NO990666D0 (no) FremgangsmÕte for diversitets-kombinering, samt mottaker
IL128500A (en) SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b] BENZOFURANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ID21353A (id) Senyawa bi-aromatik yang terikat melalui radikal heteroetilena, serta komposisi farmasi dan kosmetik yang mengandungnya
ZA836480B (en) Substituted tert.-butanol derivatives,processes for their preparation and antimycotic agents containing these compounds
BG102229A (en) Endothelium receptor antagonists
ZA200000724B (en) 6-substituted 3-methyloct-6-enols.
YU48200A (sh) Farmaceutski preparati
PL313594A1 (en) Triaryl ethylene derivatives for therapeutic applications
AP2000001746A0 (en) Anti- first-pass effect compounds.
ES2166477T3 (es) Mezclas de estabilizadores y su uso en policarbonatos.
GB2283974A (en) Allatostatins and their use
DE59602370D1 (de) Schuh-Unterkonstruktion insbesondere für Sicherheitsschuhe
RU96105380A (ru) Полимербетонная смесь для тепло- и гидроизоляций трубопроводов

Legal Events

Date Code Title Description
FD Lapse